Clinical Trial Update: Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem [Phase 2]

View source ↗

Summary

Phase 2 safety lead-in trial evaluating the addition of a repurposed drug to the lenalidomide plus pembrolizumab combination in advanced endometrial cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)
• Repurposed drug (name not disclosed)

Snippet

Sponsor: Evergreen Therapeutics, Inc. | Conditions: Advanced Endometrial Cancer | Phase 2 | Status: NOT_YET_RECRUITING